These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10955815)

  • 1. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography.
    Ikeda M; Maekawa R; Tanaka H; Matsumoto M; Takeda Y; Tamura Y; Nemori R; Yoshioka T
    Clin Cancer Res; 2000 Aug; 6(8):3290-6. PubMed ID: 10955815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
    Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ameloblastoma invasion in vitro and in vivo by inhibitor of metalloproteinase-2 activity.
    Zhang B; Zhang J; Huang HZ; Chen WL; Tao Q; Zeng DL; Zhang LT; Xu JH
    J Oral Pathol Med; 2009 Oct; 38(9):731-6. PubMed ID: 19473446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
    Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
    Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
    Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
    Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
    Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
    Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
    Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
    Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis.
    Qu XJ; Yuan YX; Tian ZG; Xu WF; Chen MH; Cui SX; Guo Q; Gai R; Makuuchi M; Nakata M; Tang W
    Int J Mol Med; 2006 Oct; 18(4):609-14. PubMed ID: 16964412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of matrix metalloproteinase activity using biotinylated gelatin.
    Ratnikov B; Deryugina E; Leng J; Marchenko G; Dembrow D; Strongin A
    Anal Biochem; 2000 Nov; 286(1):149-55. PubMed ID: 11038285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gelatinolytic activity of matrix metalloproteinase in lung cancer studied using film in situ zymography stamp method.
    Kaji M; Moriyama S; Sasaki H; Saitoh Y; Kiriyama M; Fukai I; Yamakawa Y; Mitsui A; Toyama T; Nemori R; Fujii Y
    Lung Cancer; 2003 Feb; 39(2):125-30. PubMed ID: 12581563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
    Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ
    Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines.
    Shiraga M; Yano S; Yamamoto A; Ogawa H; Goto H; Miki T; Miki K; Zhang H; Sone S
    Cancer Res; 2002 Oct; 62(20):5967-73. PubMed ID: 12384564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
    Nyormoi O; Mills L; Bar-Eli M
    Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor.
    Kohri T; Moriwaki M; Nakajima M; Tabuchi H; Shiraki K
    Graefes Arch Clin Exp Ophthalmol; 2003 Nov; 241(11):943-52. PubMed ID: 14586590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations.
    Tsai CH; Hsieh YS; Yang SF; Chou MY; Chang YC
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jun; 95(6):710-6. PubMed ID: 12789153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer.
    Kawamura K; Kamiya N; Suyama T; Shimbo M; Oosumi N; Suzuki H; Ueda T; Tobe T; Igarashi T; Ito H; Ishikura H
    J Urol; 2004 Oct; 172(4 Pt 1):1480-4. PubMed ID: 15371875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
    Zervos EE; Shafii AE; Rosemurgy AS
    J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses.
    Syggelos SA; Eleftheriou SC; Giannopoulou E; Panagiotopoulos E; Aletras AJ
    J Rheumatol; 2001 Jun; 28(6):1319-29. PubMed ID: 11409126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-hydroxyethyl methacrylate as an inhibitor of matrix metalloproteinase-2.
    Carvalho RV; Ogliari FA; de Souza AP; Silva AF; Petzhold CL; Line SR; Piva E; Etges A
    Eur J Oral Sci; 2009 Feb; 117(1):64-7. PubMed ID: 19196320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.